Search results
Showing 91 to 105 of 234 results for dementia
(off-label use) for treating neuropathic pain, migraine, depression and dementia. If valproate is taken during pregnancy, up to 4 in 10...
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.
NICE research projects and partners.
behavioural risk? What is the programme's effect on the development of dementia, disability and frailty? How feasible is extending the...
A quick guide for registered managers of care homes and home care services supporting advance care planning
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
of dementia and SPECT/CT in the imaging of parathyroid adenomas. Amit setup and leads the FDG and Amyloid PET CT service across Dorset...
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
leading to healthier ageing and preventing or delaying the development of dementia, disability and frailty in later life? How can these...
This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.